Saturday 17 October 2026
Export RGEN’s income statement to Excel — free account
Repligen Corporation
RGEN Healthcare Medical Instruments & Supplies
Repligen Corporation’s revenue for fiscal 2025 (year ended December 2025) was $738.3 million, up 16.4% from fiscal 2024. In the quarter to June 2026, revenue grew 11.9%, EPS fell 65.4%, free cash flow grew 27.1% and total debt rose 3.25%, each against the same quarter a year earlier.
175.20
8.97
−4.87%
Follow RGEN
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
188.34 | 0.00 | 267.52 | 48.21 | 113.18 | 168.10 | 205.56 | 138.79 | 50.77 | 89.00 |
Piotroski F-Score |
6 | 4 | 4 | 4 | 5 | 6 | 5 | 5 | 5 | 3 |
P/S ratio |
12.48 | 12.69 | 15.80 | 11.21 | 21.73 | 27.50 | 16.55 | 11.90 | 10.03 | 10.00 |
Altman Z-Score |
7.49 | 6.42 | 7.83 | 10.18 | 15.29 | 16.90 | 8.68 | 9.27 | 6.02 | 6.10 |
P/FCF ratio |
215.98 | 83.67 | 133.33 | 107.29 | 305.20 | 277.58 | 101.49 | 115.48 | 118.11 | 322.68 |
Altman Z″-Score (non-manufacturers) |
5.48 | 4.98 | 5.19 | 5.88 | 5.31 | 6.67 | 6.24 | 5.46 | 6.00 | 4.87 |
Beneish M-Score |
(2.52) | (2.76) | (2.42) | (2.41) | (1.75) | (1.96) | (2.53) | (2.36) | (1.25) | (2.52) |
P/Operating CF |
358.49 | 205.52 | 343.71 | 145.19 | 293.64 | 677.22 | 253.01 | 415.53 | 93.11 | 535.21 |
P/B ratio |
4.38 | 4.08 | 5.08 | 4.70 | 8.33 | 6.59 | 4.22 | 3.75 | 2.40 | 6.20 |
Price to Tangible BV |
15.22 | 14.81 | 17.50 | 12.94 | 26.37 | 16.15 | 11.80 | 15.05 | 11.86 | 13.17 |
EV/Sales |
12.27 | 12.44 | 15.53 | 10.95 | 21.36 | 26.27 | 15.43 | 11.95 | 10.20 | 9.56 |
EV/EBITDA |
60.17 | 157.32 | 82.71 | 31.63 | 65.94 | 89.22 | 64.68 | 50.38 | 58.77 | 46.90 |
EV/Operating CF |
77.15 | 44.98 | 86.19 | 51.00 | 120.35 | 153.67 | 62.06 | 70.74 | 82.56 | 132.87 |
EV/FCF |
212.32 | 81.98 | 131.03 | 104.81 | 300.03 | 265.25 | 94.66 | 115.98 | 120.09 | 308.33 |
Quick Ratio |
6.82 | 7.03 | 5.31 | 1.83 | 1.92 | 2.47 | 12.03 | 1.77 | 7.99 | 7.49 |
Current Ratio |
8.37 | 8.41 | 6.74 | 2.47 | 2.48 | 2.83 | 13.28 | 2.12 | 9.63 | 8.74 |
Net Debt/EBITDA |
(1.50) | (4.62) | (1.45) | (0.75) | (1.13) | (4.15) | (4.66) | (1.96) | (3.04) | (2.18) |
Debt/Assets |
18.38% | 18.57% | 20.47% | 16.42% | 15.15% | 14.18% | 16.91% | 13.36% | 13.35% | 32.98% |
Debt/Equity |
0.26 | 0.27 | 0.30 | 0.22 | 0.20 | 0.18 | 0.22 | 0.17 | 0.17 | 0.56 |
Asset Turnover |
0.26 | 0.22 | 0.24 | 0.33 | 0.31 | 0.22 | 0.25 | 0.26 | 0.27 | 0.48 |
Operating CF/Net income |
2.40 | (6.87) | 3.20 | 0.93 | 0.93 | 1.05 | 3.14 | 1.97 | 0.62 | 0.64 |
Capex/Depreciation |
(0.27) | (0.39) | (0.55) | (2.53) | (1.43) | (0.69) | (0.82) | (0.70) | (0.52) | (0.80) |
Interest Coverage |
2.56 | (1.69) | 19.06 | 193.35 | 14.83 | 6.48 | 3.88 | 3.87 | 2.17 | 4.24 |
| 2.40% | (1.30%) | 1.84% | 10.16% | 7.82% | 4.63% | 2.56% | 2.75% | 7.46% | 8.01% | |
| 1.69% | (0.90%) | 1.33% | 7.61% | 6.02% | 3.63% | 1.97% | 2.19% | 5.49% | 5.37% | |
ROIC |
1.83% | (1.26%) | 1.66% | 8.25% | 6.95% | 4.03% | 2.97% | 3.09% | 1.69% | 8.17% |
Return on Tangible Assets |
4.12% | (2.24%) | 3.08% | 23.70% | 18.83% | 9.22% | 3.34% | 9.33% | 11.81% | 6.56% |
Average Days of Receivables |
78.41 | 77.16 | 71.67 | 52.94 | 63.92 | 71.14 | 58.98 | 67.26 | 71.68 | 55.98 |
Research and Development Expense of Revenue |
7.34% | 6.81% | 6.76% | 5.48% | 5.11% | 5.51% | 7.20% | 8.15% | 6.14% | 7.04% |
Selling, General and Administrative Expense of Revenue |
39.35% | 41.51% | 34.57% | 26.93% | 27.42% | 32.66% | 35.38% | 33.86% | 36.47% | 29.51% |
Intangible Assets out of Total Assets |
0.51 | 0.51 | 0.49 | 0.48 | 0.51 | 0.48 | 0.49 | 0.60 | 0.63 | 0.31 |
Share Based Compensation of Revenue |
4.42% | 7.58% | 4.04% | 3.41% | 4.10% | 4.64% | 4.75% | 5.25% | 4.78% | 4.40% |
Graham Net Nets |
0.03 | 0.03 | 0.02 | 0.04 | 0.02 | 0.05 | 0.07 | 0.05 | 0.06 | 0.06 |
Graham Number |
27.08 | 0.00 | 23.06 | 51.03 | 40.92 | 27.32 | 14.90 | 10.97 | 15.94 | 6.29 |
Earnings Yield |
0.53% | (0.31%) | 0.37% | 2.07% | 0.88% | 0.59% | 0.49% | 0.72% | 1.97% | 1.12% |
Free Cash Flow Yield |
0.46% | 1.20% | 0.75% | 0.93% | 0.33% | 0.36% | 0.99% | 0.87% | 0.85% | 0.31% |
Revenue per Share |
13.13 | 11.34 | 11.35 | 14.45 | 12.19 | 6.97 | 5.59 | 4.43 | 3.69 | 3.11 |
Operating CF per Share |
2.09 | 3.14 | 2.04 | 3.10 | 2.16 | 1.19 | 1.39 | 0.75 | 0.46 | 0.22 |
Capex per Share |
(0.45) | (0.59) | (0.70) | (2.40) | (1.30) | (0.50) | (0.48) | (0.32) | (0.14) | (0.13) |
Free Cash Flow per Share |
1.63 | 2.55 | 1.34 | 0.70 | 0.87 | 0.69 | 0.91 | 0.43 | 0.31 | 0.10 |
Cash per Share |
13.65 | 13.54 | 13.48 | 11.25 | 10.98 | 13.65 | 11.12 | 4.43 | 4.54 | 4.22 |
Shareholders Equity per Share |
37.45 | 35.27 | 35.26 | 34.45 | 31.81 | 29.10 | 21.92 | 14.06 | 15.47 | 5.03 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
37.45 | 35.27 | 35.26 | 34.45 | 31.81 | 29.10 | 21.92 | 14.06 | 15.47 | 5.03 |
Free Cash Flow |
91.93 | 142.49 | 74.93 | 38.74 | 47.74 | 36.28 | 44.06 | 18.73 | 12.00 | 3.24 |
Working Capital |
1,001.56 | 939.25 | 946.40 | 593.92 | 556.42 | 583.43 | 593.52 | 145.90 | 217.57 | 163.08 |
Capital Expenditures |
(25.49) | (32.90) | (38.99) | (133.35) | (71.28) | (26.34) | (23.15) | (14.04) | (5.45) | (4.28) |
Net Current Asset Value |
293.82 | 209.09 | 245.01 | 377.22 | 323.39 | 528.65 | 301.48 | 116.69 | 90.81 | 64.00 |
EV/EBIT |
164.20 | 0.00 | 205.82 | 39.06 | 85.64 | 137.83 | 115.60 | 89.20 | 102.87 | 62.56 |
Capex to Sales |
0.03 | 0.05 | 0.06 | 0.17 | 0.11 | 0.07 | 0.09 | 0.07 | 0.04 | 0.04 |
Price to Operating Income |
167.03 | 0.00 | 209.42 | 39.99 | 87.12 | 144.24 | 123.93 | 88.82 | 101.17 | 65.47 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.51 | 0.43 | 0.34 | 0.28 | 0.40 | 0.57 | 0.59 | 0.62 | 0.47 | 0.36 |
Cash ROIC |
2.69% | 4.38% | 2.27% | 1.31% | 1.76% | 1.44% | 2.40% | 2.05% | 1.39% | 0.80% |
Accounts Receivable Turnover |
5.04 | 4.91 | 5.26 | 6.86 | 7.10 | 6.37 | 6.81 | 6.11 | 6.45 | 7.63 |
Accounts Payable Turnover |
11.33 | 13.92 | 15.02 | 10.85 | 10.52 | 11.07 | 10.87 | 9.74 | 10.86 | 8.00 |
Inventory Turnover |
2.25 | 2.08 | 1.61 | 1.64 | 2.00 | 2.09 | 2.45 | 2.13 | 2.11 | 2.21 |
Average Days of Payables |
31.12 | 32.60 | 20.18 | 29.08 | 47.31 | 39.34 | 35.01 | 44.24 | 39.64 | 39.21 |
Days of Inventory on Hand |
176.75 | 145.03 | 208.65 | 251.49 | 241.12 | 221.43 | 168.04 | 178.27 | 212.33 | 191.31 |
Average Receivables |
146.35 | 129.14 | 120.20 | 116.83 | 94.40 | 57.53 | 39.71 | 31.75 | 21.89 | 13.71 |
Average Payables |
31.07 | 25.85 | 23.56 | 31.88 | 26.54 | 14.15 | 10.96 | 8.89 | 6.17 | 5.89 |
Average Inventory |
156.71 | 172.64 | 220.30 | 211.39 | 139.76 | 74.93 | 48.55 | 40.63 | 31.85 | 21.35 |
Average Assets |
2,889.68 | 2,830.43 | 2,681.39 | 2,444.98 | 2,130.62 | 1,651.50 | 1,087.37 | 759.07 | 516.22 | 217.58 |
Average Common Equity |
2,039.42 | 1,968.78 | 1,937.77 | 1,830.38 | 1,639.61 | 1,294.46 | 837.67 | 603.56 | 380.16 | 145.76 |
Columns are period end dates